Pfizer's Phase III DMD gene therapy trial misses primary endpoint

By Yahoo! Finance | Jun 13, 2024 at 04:49 AM EST

Pfizer's Phase III trial of gene therapy for Duchenne muscular dystrophy in young boys did not meet its primary endpoint of improving motor function. Despite this, the therapy's safety profile was manageable. Pfizer aims to share detailed results to enhance future research and care for DMD patients.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.